BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. J Nucl Med 2018;59:1699-705. [PMID: 29653971 DOI: 10.2967/jnumed.118.209841] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Wen X, Shi C, Xu D, Zhang P, Li Z, Li J, Su X, Zhuang R, Liu T, Guo Z, Zhang X. Radioiodinated Portable Albumin Binder as a Versatile Agent for in Vivo Imaging with Single-Photon Emission Computed Tomography. Mol Pharm 2019;16:816-24. [PMID: 30604976 DOI: 10.1021/acs.molpharmaceut.8b01116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
2 Fani M, Mansi R, Nicolas GP, Wild D. Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. Cancers (Basel) 2022;14:1172. [PMID: 35267479 DOI: 10.3390/cancers14051172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mokoala K, Lawal I, Lengana T, Kgatle M, Giesel FL, Vorster M, Sathekge M. PSMA Theranostics: Science and Practice. Cancers (Basel) 2021;13:3904. [PMID: 34359805 DOI: 10.3390/cancers13153904] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Xu L, Meng Q, Yao X, Yang R, Zhang P, Li R, Wang F. Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China. Appl Radiat Isot 2022;179:109975. [PMID: 34741954 DOI: 10.1016/j.apradiso.2021.109975] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kramer V, Fernández R, Lehnert W, Jiménez-Franco LD, Soza-Ried C, Eppard E, Ceballos M, Meckel M, Benešová M, Umbricht CA, Kluge A, Schibli R, Zhernosekov K, Amaral H, Müller C. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging 2021;48:893-903. [PMID: 32949253 DOI: 10.1007/s00259-020-05022-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Unterrainer M, Niyazi M, Tonn JC, Ilhan H, Bartenstein P, Albert NL. A look ahead: future directions of SSR-directed imaging and therapy in meningioma. Clin Transl Imaging 2019;7:357-62. [DOI: 10.1007/s40336-019-00333-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med 2019;60:377-85. [PMID: 30115686 DOI: 10.2967/jnumed.118.215848] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
8 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
9 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Davis RA, Hausner SH, Harris R, Sutcliffe JL. A Comparison of Evans Blue and 4-(p-Iodophenyl)butyryl Albumin Binding Moieties on an Integrin αvβ6 Binding Peptide. Pharmaceutics 2022;14:745. [DOI: 10.3390/pharmaceutics14040745] [Reference Citation Analysis]
11 Liu Q, Cheng Y, Zang J, Sui H, Wang H, Jacobson O, Zhu Z, Chen X. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2020;47:947-57. [PMID: 31832728 DOI: 10.1007/s00259-019-04530-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers (Basel) 2022;14:1055. [PMID: 35205805 DOI: 10.3390/cancers14041055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Artiko V, Sobic-Saranovic D, Pavlovic S, Petrovic M, Zuvela M, Antic A, Matic S, Odalovic S, Petrovic N, Milovanovic A, Obradovic V. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC. J BUON. 2012;17:537-542. [PMID: 23033296 DOI: 10.1016/j.clinimag.2018.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Wang Z, Jacobson O, Tian R, Mease RC, Kiesewetter DO, Niu G, Pomper MG, Chen X. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG. Bioconjug Chem 2018;29:2309-15. [PMID: 29865797 DOI: 10.1021/acs.bioconjchem.8b00292] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
15 Wang H, Cheng Y, Zhang J, Zang J, Li H, Liu Q, Wang J, Jacobson O, Li F, Zhu Z, Chen X. Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. Theranostics 2018;8:3308-16. [PMID: 29930731 DOI: 10.7150/thno.25919] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
16 Kotzerke J, Runge R, Braune A, Wunderlich G. Different Radionuclides in DOTA-EB-TATE Effect Different Uptake in Somatostatin Receptor-Positive HEK293 Cells. J Nucl Med 2019;60:436. [PMID: 30442758 DOI: 10.2967/jnumed.118.220707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Tian R, Zhu S, Zeng Q, Lang L, Ma Y, Kiesewetter DO, Liu Y, Fu X, Lau J, Zhu G, Jacobson O, Wang Z, Dai Y, Yu G, Brooks BR, Liu G, Niu G, Chen X. An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides. Bioconjug Chem 2019;30:1711-23. [PMID: 31082207 DOI: 10.1021/acs.bioconjchem.9b00258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
18 Nicolas GP, Morgenstern A, Schottelius M, Fani M. New Developments in Peptide Receptor Radionuclide Therapy. J Nucl Med 2019;60:167-71. [DOI: 10.2967/jnumed.118.213496] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
19 Taïeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer 2019;26:R627-52. [PMID: 31561209 DOI: 10.1530/ERC-19-0165] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 12.5] [Reference Citation Analysis]
20 Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, Zhang J, Cheng Y, Zhu Z, Chen X. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE. J Nucl Med 2021;62:386-92. [PMID: 32826319 DOI: 10.2967/jnumed.120.248658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Das S, Al-Toubah T, El-Haddad G, Strosberg J. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2019;13:1023-31. [PMID: 31652074 DOI: 10.1080/17474124.2019.1685381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
22 Brandt M, Cardinale J, Giammei C, Guarrochena X, Happl B, Jouini N, Mindt TL. Mini-review: Targeted radiopharmaceuticals incorporating reversible, low molecular weight albumin binders. Nucl Med Biol 2019;70:46-52. [PMID: 30831342 DOI: 10.1016/j.nucmedbio.2019.01.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
23 Brandt F, Ullrich M, Laube M, Kopka K, Bachmann M, Löser R, Pietzsch J, Pietzsch HJ, van den Hoff J, Wodtke R. "Clickable" Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. J Med Chem 2021. [PMID: 34939412 DOI: 10.1021/acs.jmedchem.1c01791] [Reference Citation Analysis]
24 Wang S, Liu Y, Feng Y, Zhang J, Swinnen J, Li Y, Ni Y. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers (Basel) 2019;11:E1782. [PMID: 31766180 DOI: 10.3390/cancers11111782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
25 Jacobson O, Chen X. Reply: Different Radionuclides in DOTA-EB-TATE Effect Different Uptake in Somatostatin Receptor-Positive HEK293 Cells. J Nucl Med 2019;60:436-7. [PMID: 30573643 DOI: 10.2967/jnumed.118.223453] [Reference Citation Analysis]
26 Bandara N, Jacobson O, Mpoy C, Chen X, Rogers BE. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent. Bioconjug Chem 2018;29:2448-54. [PMID: 29927587 DOI: 10.1021/acs.bioconjchem.8b00341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
27 Hänscheid H, Hartrampf PE, Schirbel A, Buck AK, Lapa C. Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC. Eur J Nucl Med Mol Imaging 2021;48:2566-72. [PMID: 33452632 DOI: 10.1007/s00259-020-05177-z] [Reference Citation Analysis]
28 Lau J, Jacobson O, Niu G, Lin KS, Bénard F, Chen X. Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. Bioconjug Chem 2019;30:487-502. [PMID: 30616340 DOI: 10.1021/acs.bioconjchem.8b00919] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
29 Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of Somatostatin Signalling in Neuroendocrine Tumours. Int J Mol Sci 2022;23:1447. [PMID: 35163374 DOI: 10.3390/ijms23031447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Malcolm J, Falzone N, Lee BQ, Vallis KA. Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. Cancers (Basel) 2019;11:E268. [PMID: 30823564 DOI: 10.3390/cancers11020268] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
31 Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics 2018;8:6088-100. [PMID: 30613284 DOI: 10.7150/thno.30357] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
32 Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther Adv Med Oncol 2021;13:17588359211018047. [PMID: 34093744 DOI: 10.1177/17588359211018047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Rousseau E, Lau J, Zhang Z, Uribe CF, Kuo H, Zhang C, Zeisler J, Colpo N, Lin K, Bénard F. Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE. Nuclear Medicine and Biology 2018;66:10-7. [DOI: 10.1016/j.nucmedbio.2018.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
34 Hu H, Quintana J, Weissleder R, Parangi S, Miller M. Deciphering albumin-directed drug delivery by imaging. Adv Drug Deliv Rev 2022;185:114237. [PMID: 35364124 DOI: 10.1016/j.addr.2022.114237] [Reference Citation Analysis]
35 Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, Liu Z. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Eur J Nucl Med Mol Imaging 2021. [PMID: 34746969 DOI: 10.1007/s00259-021-05591-x] [Reference Citation Analysis]
36 Abbasi Gharibkandi N, Conlon JM, Hosseinimehr SJ. Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy. Peptides 2020;133:170385. [PMID: 32822772 DOI: 10.1016/j.peptides.2020.170385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]